PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 1 - 3 of 3 results
News
|
|
3 min read
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
Press Release
|
|
6 min read
The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.
News
|
|
3 min read